2016 International Congress

Thursday, June 23, 2016

12:00pm-1:30pm

Clinical course and treatment of 6 children with GNAO1 mutations causing a severe, life-threatening chorea

A. Robichaux-Viehoever, A. Ananth, Y.M. Kim, A. Hanson-Kahn, R. Cox, G. Enns, J. Strober, M. Willing, B. Schlaggar, J. Bernstein, Y. Wu (San Francisco, CA, USA)

Pediatric movement disorder  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Clinical effect and dose conversion of rytary (numient) in 50 consecutive patients with PD motor fluctuations

N. Chhabria, S.H. Isaacson (Boca Raton, FL, USA)

Parkinson's disease: Clinical trials, pharmacology and treatment  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Clinical effects of pallidal stimulation in dystonia are quantitatively related to intracortical inhibition

A. Fecíková, V. Cejka, V. Capek, F. Ruzicka, V. Bocek, D. Štastná, I. Štetkárová, D. Urgošík, R. Jech (Praha, Czech Republic)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Clinical outcomes of pallidal and subthalamic nucleus deep brain stimulation in isolated cranial and cranio-cervical dystonia

N.S. Luthra, K.A. Dodenhoff, M. San Luciano, M.M. Volz, S.L. Heath, P.A. Starr, J.L. Ostrem (San Francisco, CA, USA)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Clinical profile of patients with writer’s cramp

H.S. Kaleagasi, O. Dogu (Mersin, Turkey)

Dystonia  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Cognitive behavioural thrapy and adiunctive physical therapy for functional movement disorders

R. Erro, M. Tinazzi, C. Dallocchio (London, United Kingdom)

Clinical trials and therapy in movement disorders  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Cognitive effects of AG-0029 in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

E.Y. Pioli, S.M.J. Camus, J. Yang, Q. Li, A. Crossman, E. Bezard, S. Hogg (Manchester, United Kingdom)

Neuropharmacology  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Cognitive effects of pramipexole in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

E.Y. Pioli, S.M.J. Camus, J. Yang, Q. Li, A. Crossman, E. Bezard (Manchester, United Kingdom)

Neuropharmacology  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Colonic α-synuclein: A potential diagnostic biomarker in Parkinson’s disease

C. Ruffmann, I. Poggiolini, N. Bengoa-Vergniory, F. Baig, M. Rolinski, J. Klein, M.T. Hu, R. Wade-Martins, J. Alegre-Abarrategui, L. Parkkinen (Oxford, United Kingdom)

Other  ·  Exhibit Hall located in Hall B, Level 2

12:00pm-1:30pm

Combinative therapy of memantine and galantamine hydrobromide as a tool of choice for the treatment of vascular parkinsonism with early appearance of dementia symptoms

A. Turakhanov, S. Dadajonov, R. Sadikov, R. Khodjaev, S. Nurov (Tashkent, Uzbekistan)

Neuropharmacology  ·  Exhibit Hall located in Hall B, Level 2